Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Cayenne Medical Launches CrossFix™ System For Repair Of Meniscal Tears
Cayenne Medical, Inc., a privately held sports medicine company based in Scottsdale, announced the commercial launch of its CrossFix™ System for the repair of meniscal tears at the American Orthopaedic Society for Sports Medicine (AOSSM) annual meeting in Keystone, Colorado last week.
generic viagra online
Researchers Edit Genes In Human Stem Cells
Researchers at the Johns Hopkins School of Medicine have successfully edited the genome of human- induced pluripotent stem cells, making possible the future development of patient-specific stem cell therapies. Reporting this week in Cell Stem Cell, the team altered a gene responsible for causing the rare blood disease paroxysmal nocturnal hemoglobinuria, or PNH, establishing for the first time a useful system to learn more about the disease.
News of the day
Fate Therapeutics Announces First Patient Treated In Phase 1b Clinical Trial Of FT1050 For Hematopoietic Stem Cell Support
Fate Therapeutics, Inc. announced that the first patient has been treated in a Phase 1b clinical trial of FT1050, a small molecule Stem Cell Modulator (SCM) designed to increase hematopoietic stem cell (HSC) number and function through its activation of key pathways that guide cell fate. The study, which is being conducted at the Dana-Farber Cancer Institute in Boston, Massachusetts, will determine the safety and tolerability of introducing FT1050 during the standard course of dual umbilical cord blood transplant in adult patients with hematologic malignancies, such as leukemia and lymphoma, who have undergone nonmyeloablative conditioning therapy. Fate Therapeutics is developing FT1050 to improve the overall efficiency of HSC treatment by enhancing HSC proliferation and homing to the bone marrow.
Endocrinology

Technology Similar To An Inkjet Printer Could Aid Toxin Detection

If that office inkjet printer has become just another fixture, it"s time to take a fresh look at it. Similar technology may soon be used to develop paper-based biosensors that can detect certain harmful toxins that can cause food poisoning or be used as bioterrorism agents. In a paper published in the July issue of Analytical Chemistry, John Brennan and his research team at McMaster University, working with the Sentinel Bioactive Paper Network, describe a method for printing a toxin-detecting biosensor on paper using a FujiFilm Dimatix Materials Printer. The researchers demonstrated the concept on the detection of acetylcholinesterase (AChE) inhibitors such as paraoxon and aflatoxin B1 on paper using a "lateral flow" sensing approach similar to that used in a home pregnancy test strip. The process involves formulating an ink like the one found in computer printer cartridges but with special additives to make the ink biocompatible. An ink comprised of biocompatible silica nanoparticles is first deposited on paper, followed by a second ink containing the enzyme, and the resulting bio-ink forms a thin film of enzyme that is entrapped in the silica on paper. When the enzyme is exposed to a toxin, reporter molecules in the ink change colour in a manner that is dependent on the concentration of the toxin in the sample. This simple and cost-effective method of adhering biochemical reagents to paper is expected to bring the concept of bioactive paper a significant step closer to commercialization. The goal for bioactive paper is to provide a rapid, portable, disposable and inexpensive way of detecting harmful substances, including toxins, pathogens and viruses, without the need for sophisticated instrumentation. The research showed that the printed enzyme retains full activity for at least two months when stored properly, suggesting that such sensor strips should have a good shelf life. Portable bio-sensing papers are expected to be extremely useful in monitoring environmental and food-based toxins, as well as in remote settings in less industrialized countries where simple bioassays are essential for the first stages of detecting disease. Applications for bioactive paper also include clinical applications in neuroscience, drug assessment, and pharmaceutical development. Gene Nakonechny McMaster University


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009